Apricus Biosciences, Topotarget deal
Apricus acquired Topotarget's Topotarget USA Inc. subsidiary in a stock deal valued at $2 million up front and up to an additional $2 million in stock based on milestones. Apricus gains all North and South American assets to Totect dexrazoxane, which is marketed in the U.S. to treat extravasation of anthracycline chemotherapeutics, as well as the subsidiary's sales infrastructure and sales team. Topotarget USA, which becomes a wholly-owned subsidiary of Apricus, will change its name to Apricus Pharmaceuticals USA Inc.
Apricus' cancer pipeline includes PrevOnco, which is lansoprazole formulated with the company's NexACT delivery technology, to treat hepatocellular carcinoma (HCC). Apricus said it is in discussions with FDA for an SPA for a Phase III trial of PrevOnco in HCC. ...